"Modest" market acceptance. Translation: zero. So little market acceptance, that for the last 6 months, they decided it wiser to peddle generic Covid swabs. But it's pure gaslighting BS to attribute Prizma's failure to Covid -- when Covid, by any honest logic, should be a major driver of remote monitoring. Zoom calls? Heard of them? Somehow this business boomed without anyone having to send sales reps to shake germ-ridden hands with hospital staff. The idea that the retreat of Covid is what will boost Prizma, is utterly twisted pretzel logic, like saying that peace-time will aid the sale of weapons and ammunition. But the truth is, the market will see this report for the bought-and-paid-for toilet paper that it is. Prediction: Heartbuds AK, whatever, won't eventuate. Prediction: Unity Point trial from April 2021, won't eventuate. Prediction: VSMS won't eventuate. It will only ever continue to be "in development."
GMV Price at posting:
3.9¢ Sentiment: None Disclosure: Held
